Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IOL Chemicals and Pharmaceuticals Limited (IOLCP.NS)
Ludhiana, IN
Established in 1986 and headquartered in Ludhiana, India, IOL Chemicals and Pharmaceuticals Limited operates as a global manufacturer and supplier of diverse pharmaceutical and chemical products. Its pharmaceutical portfolio encompasses a wide array of active pharmaceutical ingredients (APIs), featuring prominent pain and fever relievers such as ibuprofen, ibuprofen lysinate, ibuprofen sodium, and dex-ibuprofen. The company also provides other crucial APIs, including metformin hydrochloride, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, lamotrigine, and fenofibrate. These compounds are integral to treatments addressing various conditions, such as inflammation, pain relief, fever reduction, diabetes, platelet aggregation, cholesterol management, seizures, gallstones, and gastric acid inhibition. In addition to pharmaceuticals, IOL supplies specialized industrial chemicals like ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid. These chemicals are widely utilized across numerous industries, including food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and as chemical intermediates.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.73% | +14.52% | +52.69% | +83.82% | +48.54% | +65.40% | +56.09% | +52.96% | +4.98% | +457.17% | +1,127.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+12.1% ★ Q1'26: +17.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+36.3% ★ Q1'26: +69.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.8% ★ Q1'26: -8.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.1% Q1'26: +10.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.1% ★ Q1'26: +11.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-80.0% ★ Q1'26: -66.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.50× ★ Q1'26: 0.40× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.85B
est: 6.33B (-39.2%)
|
5.80B
est: 6.33B (-8.2%)
|
7.02B
est: 6.96B (+0.9%)
|
9.62B
est: 9.66B (-0.4%)
|
16.85B
est: 16.84B (+0.1%)
|
18.94B
est: 19.13B (-1.0%)
|
19.46B
est: 20.65B (-5.8%)
|
21.84B
est: 21.38B (+2.2%)
|
22.02B
est: 22.05B (-0.2%)
|
21.19B
est: 23.96B (-11.6%)
|
20.68B
est: 21.00B (-1.5%)
|
23.04B
23.04B – 23.04B
+9.7% YoY
|
25.77B
25.77B – 25.77B
+11.9% YoY
|
28.90B
28.90B – 28.90B
+12.1% YoY
|
| EBITDA |
-55.04M
est: 988.22M (-105.6%)
|
365.71M
est: 988.22M (-63.0%)
|
979.10M
est: 1.09B (-9.9%)
|
1.20B
est: 1.51B (-20.5%)
|
4.15B
est: 2.63B (+57.8%)
|
5.85B
est: 2.99B (+95.7%)
|
6.11B
est: 5.92B (+3.3%)
|
2.71B
est: 3.34B (-19.0%)
|
2.46B
est: 7.19B (-65.8%)
|
2.61B
est: 5.92B (-55.9%)
|
2.25B
est: 2.45B (-8.2%)
|
2.69B
2.69B – 2.69B
+9.7% YoY
|
3.01B
3.01B – 3.01B
+11.9% YoY
|
3.37B
3.37B – 3.37B
+12.1% YoY
|
| EBIT |
-344.15M
est: 829.74M (-141.5%)
|
68.85M
est: 829.74M (-91.7%)
|
680.70M
est: 912.72M (-25.4%)
|
903.00M
est: 1.27B (-28.7%)
|
3.83B
est: 2.21B (+73.3%)
|
5.49B
est: 2.51B (+118.9%)
|
5.72B
est: 2.71B (+111.3%)
|
2.27B
est: 2.80B (-18.9%)
|
1.99B
est: 7.06B (-71.8%)
|
1.98B
est: 3.14B (-37.1%)
|
1.53B
est: 1.86B (-17.9%)
|
2.04B
2.04B – 2.04B
+9.7% YoY
|
2.28B
2.28B – 2.28B
+11.9% YoY
|
2.56B
2.56B – 2.56B
+12.1% YoY
|
| Net Income |
-666.51M
est: 2.84B (-123.5%)
|
-400.26M
est: 2.84B (-114.1%)
|
46.70M
est: 755.09M (-93.8%)
|
277.00M
est: 1.22B (-77.3%)
|
2.37B
est: 9.36B (-74.7%)
|
3.61B
est: 18.88B (-80.9%)
|
4.45B
est: 22.49B (-80.2%)
|
1.68B
est: 10.46B (-84.0%)
|
1.39B
est: 4.74B (-70.6%)
|
1.34B
est: 5.20B (-74.1%)
|
1.01B
est: 956.73M (+5.6%)
|
1.29B
1.29B – 1.29B
+35.0% YoY
|
1.53B
1.53B – 1.53B
+18.2% YoY
|
1.79B
1.79B – 1.79B
+17.3% YoY
|
| SGA |
8.94M
est: 390.98M (-97.7%)
|
7.13M
est: 390.98M (-98.2%)
|
217.40M
est: 430.08M (-49.5%)
|
347.40M
est: 596.83M (-41.8%)
|
481.80M
est: 1.04B (-53.7%)
|
508.90M
est: 1.18B (-57.0%)
|
1.16B
est: 1.28B (-9.4%)
|
713.40M
est: 1.32B (-46.0%)
|
1.69B
est: 2.94B (-42.6%)
|
2.03B
est: 1.48B (+36.9%)
|
924.10M
est: 1.62B (-42.9%)
|
1.78B
1.78B – 1.78B
+9.7% YoY
|
1.99B
1.99B – 1.99B
+11.9% YoY
|
2.23B
2.23B – 2.23B
+12.1% YoY
|
| EPS |
-16.72
est: 1.93 (-966.3%)
|
-7.60
est: 1.93 (-493.8%)
|
0.83
est: 0.51 (+61.5%)
|
4.93
est: 0.83 (+492.5%)
|
42.11
est: 6.37 (+560.7%)
|
63.51
est: 12.85 (+394.1%)
|
15.24
est: 15.31 (-0.4%)
|
5.71
est: 7.12 (-19.8%)
|
4.74
est: 3.53 (+34.3%)
|
4.58
est: 6.32 (-27.5%)
|
3.44
est: 3.26 (+5.5%)
|
4.40
4.40 – 4.40
+35.0% YoY
|
5.20
5.20 – 5.20
+18.2% YoY
|
6.10
6.10 – 6.10
+17.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kushal Kumar Rana | Director of Works & Wholetime Director | 18M | male |
| Abhiraj Gupta | Executive Director | 14M | male |
| Gopal Singla | President of Engineering | — | male |
| Gurupur Ganesh Pai | Chief Technology Officer | — | — |
| Kamlesh Jayantilal Ranbhan | President of R&D | — | male |
| Pardeep Kumar Khanna | Chief Financial Officer | — | male |
| Varinder Gupta | MD & Whole Time Director | — | male |
| Abhay Raj Singh | Senior Vice President, Company Secretary & Compliance Officer | — | male |
| Vikas Gupta | Joint Managing Director & Executive Director | — | male |
| Damandeep Singh | President of New Product Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IOLCP.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
